Skip to main content

Table 1 Advanced stage ovarian cancer cohort, demographic characteristics and healthcare utilization (N=12,659)

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

Characteristics

N (%)

Total advanced incident cancer cases from January 1, 2010 to January 31, 2018 (N, %)a,b

 

Advanced stage at diagnosis, N (%)c

12,237 (96.67%)

Diagnosed as early stage and progressed to advanced stage, N (%)

422 (3.33%)

Age (years)

 Mean (SD)

61.94 (14)

 Q1

53

 Median

62

 Q3

72

Region

 Midwest

3436 (28.48%)

 Northeast

2293 (19.01%)

 South

2976 (24.67%)

 West

3358 (27.84%)

Year of index date

 2010-2011

4712 (37.22%)

 2012-2014

4468 (35.30%)

 2015-2018

3479 (27.48%)

Plan type

 Commercial

9288 (73.37%)

 Medicare Advantage

1511 (11.94%)

 Medicare, Other

1860 (14.69%)

Duration of health plan membership prior to advanced stage index date (months)

 Mean (SD)

48.16 (28.25)

 Q1

23.24

 Median

48.20

 Q3

68.86

Duration of follow-up (months)

 Mean (SD)

24.52 (23.28)

 Q1

6.47

 Median

17.25

 Q3

35.19

Deyo-Charlson Comorbidity Index (DCI) during follow-up

 Mean (SD)

6.34 (2.63)

 Q1

5

 Median

6

 Q3

8

Number of drugs dispensed during follow-up

 Mean (SD)

12.61 (9.76)

 Q1

5

 Median

11

 Q3

18

  1. Abbreviations: N Number, SD Standard deviation, US United States, Q Quartile, ED Emergency department.
  2. aThe cohort includes patients who had at least one ICD-9-CM or ICD-10 diagnosis code for ovarian cancer, were continuously enrolled in a health plan contributing data to the HIRD for at least six months, and were confirmed to have advanced ovarian cancer based on staging information from either a cancer registry or the HIRE Oncology data or met the predictive model algorithm for advanced stage ovarian cancer.
  3. bIncident cases are individuals for whom at least six months of data were available in the HIRD prior to the first diagnosis of ovarian cancer in claims.
  4. cCases are defined as "advanced stage at diagnosis" if their advanced stage date (from cancer registry, HIRE Oncology, or predictive model) was within one month of their first cancer diagnosis in claims, otherwise they are defined as "Diagnosed as early stage and progressed to advanced stage".